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TO THE EDITOR
Extranodal NK/T-cell lymphoma, nasal type (NK-NHL), is a rare disease in North America and Europe, but is not uncommon in Asia and South America. This lymphoma is characterized by extranodal presentation, angiocentric and angiodestructive proliferation of cells including large granular lymphocytes, and rather characteristic pheno-and genotypes characterized by CD2+, CD3e + , surface CD3À, CD16À/+, CD56+, CD57À, and the absence of clonal rearrangements of T-cell receptor (TCR) genes. Clinically, localized NK-NHL is usually sensitive to radiation therapy. However, the prognosis is usually poor once dissemination occurs, and long-term remission even with aggressive chemotherapy is rare. At present, an elevated serum LDH level and the presence of B symptoms are known to be poor prognostic factors. We previously found that a differentiation inhibitory factor (I-factor) purified from a differentiation-resistant mouse myelogenous leukemia cell line was identical to nm23 protein. 1 Recently, we established an enzyme-linked immunosorbent assay (ELISA) technique of determining the serum level of nm23-H1 protein, 2 and reported that the level in patients with aggressive lymphoma was significantly higher than that in healthy individuals. Furthermore, this assay system can be useful to determine the therapeutic strategy for aggressive lymphoma since the prognosis is worse in patients with a high nm23-H1 level. In the present study, we report that the serum level of nm23-H1 was elevated in patients with NK-NHL, and that the level was significantly correlated with the clinical outcome. It is suggested by these findings that the serum level of nm23-H1 may be a valuable prognostic factor for patients with NK-NHL.
In all, 60 untreated NK-NHL patients who were consecutively enrolled and managed by the Adult Lymphoma Treatment Study Group (ALTSG) in Japan from 1988 to 2000 were the subject of the present study. The patients consisted of 31 males and 29 females with a median age of 49 years (range: 15-88 years). A brief summary 
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of the clinicopathological characteristics of the patients is given in The serum nm23-H1 level of the patients with NK-NHL (n ¼ 60, 59.73737.47 ng/ml) was significantly higher than that of the healthy controls (n ¼ 45, 3.8974.06 ng/ml; P ¼ 0.00001). Table 1 shows the clinicopathological features of the 60 patients. The nm23-H1 protein level was correlated with advanced stage of the disease (P ¼ 0.0001) ( Table 1) . Complete remission (CR) was achieved in 35 (58.3%) of the 60 patients, and the median serum level of nm23-H1 in these 35 patients was 42.0 ng/ml at the time of diagnosis. This value was significantly lower than that in patients who showed partial remission (PR) or failed to respond (86.0 ng/ml, P ¼ 0.0144), suggesting a close relation between the serum level of nm23-H1 and therapeutic responsiveness. The relation between the nm23-H1 level and other known serum markers of the NK-NHL patients was examined. There was a weak, but significant, correlation between nm23-H1 and the soluble interleukin-2 receptor (sIL-2R) level (r ¼ 0.454, P ¼ 0.00027), but no correlation was evident between the nm23-H1 level and LDH (r ¼ 0.196, NS) (data not shown). In all 60 NK-NHL patients, the 10-year overall survival (OS) and progression-free survival (PFS) rates were 35.5 and 25.5%, respectively. The patients were classified into two groups according to the serum nm23-H1 level using various cut-off values, such as 46.0 ng/ml (median, o46.0, n ¼ 31 vs X46.0, n ¼ 29), 59.73 ng/ml (mean, o59.73, n ¼ 34 vs X59.73, n ¼ 26), and 80 ng/ml (o80, n ¼ 38 vs X80, n ¼ 22), and it was found that all the cut-off values had significant prognostic effects. The 10-year OS rates of the high (X80, n ¼ 22) and low nm23-H1 groups (o80, n ¼ 38) were 0 and 49.4%, respectively (P ¼ 0.0001), with 10-year PFS rates of 0 and Correspondence 38.1%, respectively (P ¼ 0.0001). We evaluated the significance of the serum nm23-H1 level in patients classified according to the IPI. In the L+L-I risk group, both the OS (Figure 1a ) and PFS ( Figure 1b) were worse among patients with an nm23-H1 level of 80 ng/ml or higher than those with a level lower than 80 ng/ml (Po0.05), indicating that the therapeutic outcome was worse when the nm23-H1 level was high. Similar results were obtained in the H-I+H risk group (Figures 1c and d) . Thus, we could predict the therapeutic outcome in both L+L-I and H-I+H risk groups of IPI using the cut-off value of 80 ng/ml at diagnosis. As to the type of therapy, the patients who underwent radiotherapy after chemotherapy had significantly better prognosis than those without radiotherapy. As to the combination of chemotherapeutic agent, patients who underwent the COP-BLAM regimen had significantly better prognosis than those who underwent the CHOP regimen. Univariate analysis was performed to assess the predictive power of the serum nm23-H1 level and other prognostic factors. Both OS and PFS were significantly worse in patients with age over 60 years, poor PS, elevated serum LDH level, advanced stage, more than one extranodal site, an IPI classification of H-I+H risk, and an nm23-H1 level of 80.0 ng/ml or higher ( Table 2 ). These seven prognostic factors were further evaluated for their association with survival by multivariate analysis using Cox's proportional hazard model. This analysis showed that the elevated serum nm23-H1 level was the most important and independent prognostic determinant for poor OS and poor PFS (data not shown) in patients with NK-NHL. Several differences in the clinical significance of the serum nm23 level between NK-NHL in the present study and aggressive lymphoma other than NK-NHL in the previous studies were found. The following are the features of NK-NHL: (1) little or no correlation between serum nm23 level and IPI scores, (2) no correlations between the median of serum nm23-H1 level and PS, LDH level, or IPI among the clinical characteristics studied and (3) no correlation between the serum LDH and serum nm23-H1 levels. These features suggest that the biological characteristics of NK-NHL are different from those of other lymphomas and that the IPI score is less useful to select treatment for this type of lymphoma.
In the present study, the serum nm23-H1 level of the NK-NHL patients was significantly higher than that in patients with diffuse large B-cell lymphoma (DLBCL) and was nearly equal to the level in patients with peripheral T-cell lymphoma (PTCL). 3 We previously reported that the nm23-H1 protein was strongly expressed on the surface of neoplastic cells of PTCL and extranodal NK/T-cell lymphomas, 4 and we also observed a significant correlation between the serum nm23-H1 level and the degree of its cell surface expression. This suggested that the serum nm23-H1 level reflects the proliferation rate of lymphoma cells, and that, in PTCL and NK-NHL, large amounts of nm23-H1 molecules are secreted from the neoplastic cells. In order to determine whether the nm23-H1 protein in serum is actually derived from tumor cells, we previously transplanted a human B lymphoma cell line, which strongly expressed nm23-H1, into nude mice and measured the level of human nm23-H1 in the recipient serum. 5 Consequently, the serum nm23-H1 protein was derived from the transplanted human lymphoma cells since the antibody used in our ELISA system specifically detected human nm23 protein (nm23-H1) but not mouse nm23 protein (nm23-M1). These results strongly suggest that the serum nm23-H1 protein is directly derived from tumor cells. OS, overall survival; PFS, progression-free survival.
Correspondence
Although this possibility can be expanded to the speculation that the serum nm23 protein level reflects the tumor burden, it was not correlated with the serum LDH level in NK-NHL, in which the serum nm23-H1 level increased with progression of the disease, but it was not correlated with the serum LDH level. Therefore, it is more likely that the serum nm23-H1 level reflects the tumor proliferation rate rather than tumor burden at least in NK-NHL. 6 We previously investigated mdr1, mrp, gst-p, topo I, topo IIa, and topo IIb expression in AML patients by RT-PCR, but none of these drug resistance-related genes were associated with cellular nm23-H1 expression. However, it is of interest to examine the relation between the levels of previously reported drug resistance-related genes and the serum nm23-H1 level because there was a significant correlation between the therapeutic response and the serum nm23-H1 level. The nm23-H1 protein level was lower in CR patients than in non-CR patients, and the prognosis was poor with regard to both OS and PFS in patients with an nm23-H1 level equal to or greater than 80 ng/ml. Thus, we employed 80 ng/ml as a cut-off value and investigated the effect of serum nm23-H1 level on OS and PFS of patients who were separated into two groups according to their IPI values (L+L-I and H-I+H risk groups) (Figure 1) . Although the number of cases in the H-I+H risk group was small, patients with nm23-H1 protein level equal to or greater than 80 ng/ml showed poor prognosis in both of the two groups. It is, therefore, considered that patients with a high nm23-H1 protein level may require more aggressive treatment than the CHOP regimen and radiation may be necessary. Multivariate analysis demonstrated that the nm23-H1 level was an independent prognostic factor for NK-NHL. Based on these findings, we propose that determination of the serum nm23-H1 protein level is important for planning the treatment strategy for individual patients with NK-NHL.
Recently, nm23 has been investigated as a molecular target for inhibition of metastasis in breast cancer and melanoma. Many chemotherapeutic agents have been screened using the nm23 expression level as an indicator of metastatic potential. 7 In hematological malignancies, it might be a novel approach to identify the compounds with preferential inhibitory activity against overexpressed nm23. On the other hand, inhibition of nm23 expression by using antisense oligonucleotide treatment or by using transfection with a plasmid vector expressing the human nm23 antisense mRNA has been tried. 8 In leukemia, as a preliminary, tried to inhibit nm23 gene expression by nm23 antisense S-oligonucleotide, leading to suppression of proliferation and promotion of differentiation (data not shown). Therefore, overexpression of the nm23 gene may be a new molecular target for leukemia treatment and, in NK-NHL, the development of a new treatment regimen that targets nm23 overexpression is expected.
